Current evidence shows no established direct mechanism by which semaglutide reduces oestrogen production
Ducatman BS, Scheithauer BW, Piepgras DG, et al
Starting doses and titration schedules differ between the two medications because their mechanisms and potency are distinct
The scatter plots of post-hoc pairwise comparison revealed that the BMI, TC, FBG, HbA1c, 2hPPG, FINS, AUC for plasma GLP-1, HOMA-IR, and WBISI significantly decreased in both treatment groups at 24 and 48 weeks compared with those at baseline
The presence of destructive or deforming arthritis warrants more aggressive therapy with either a nonbiologic DMARD or a TNF inhibitor, although there is far less evidence for the prevention of structural damage with conventional DMARDs
Dual approaches in oncology: the promise of siRNA and chemotherapy combinations in cancer therapies